Melissa Abel, MD (@melissaabel20) header
Melissa Abel, MD (@melissaabel20) profile picture

Medical oncologist studying prostate cancer @ the NIH | @UCLAhealth IM | @Dukemedschool | Road Trip enthusiast, Oregonian.

Washington, DC
Joined May 2019
Photo by Melissa Abel, MD (@melissaabel20)Photo by Melissa Abel, MD (@melissaabel20)Photo by Melissa Abel, MD (@melissaabel20)Photo by Melissa Abel, MD (@melissaabel20)Photo by Melissa Abel, MD (@melissaabel20)
Melissa Abel, MD retweeted
#APCCC2026: How much consensus is there in high-risk prostate cancer? 🌍 133 experts, 134 questions, and consensus on only 33%. 💡 Where do we stand on treatment intensification, PSMA-PET, radiotherapy and biomarkers? doi.org/10.1016/j.eururo.202… @OncoAlert
1
8
31
2,252
Melissa Abel, MD retweeted
#ESMO26 Personalized Systemic Therapy for mHSPC @AOmlin @urotoday Two Practice Decision Frameworks: 🔔High volume mHSPC in fit pts 🔔Low volume mHSPC in fit pts
46
1
75
4,341
Melissa Abel, MD retweeted
#ESMO26 PROTEUS discussion by Nicholas van As • No baseline PSMA PET; enrolled conventionally staged M0 • MFS events: true progression or delayed detection? Most were PSMA PET-detected (8.8% vs 16.3%) • TTST HR 0.29, but ~20-mo lead-time bias #ProstateCancer
3
25
2
55
4,346
Melissa Abel, MD retweeted
Putting STAMPEDE, ENZARAD, PROTEUS & DASL into context with the latest #ESMO26 updates: STAMPEDE: Abiraterone-based intensification improved MFS AND OS, predominantly with RT. New #ESMO26 Decipher data suggests differential abi benefit in cN0 disease (interaction P=.01); using this to omit treatment still requires validation. ENZARAD: At 8 years, MFS was 74% vs 72% (HR 0.88; P=.34). No significant overall MFS benefit from enza + ADT/RT. The cN1/planned pelvic RT subgroup signals remain hypothesis-generating. DASL: new at #ESMO26: 1,106 patients; 96 weeks of daro v. placebo + ADT + prostate/bed AND pelvic RT. Four-year conventional-imaging MFS: 95% vs 88% (HR 0.42). Very-high-risk population, including selected postoperative patients. Interim analysis; OS immature. PROTEUS main trial: Perioperative apa + ADT improved 5-year PSMA-inclusive MFS versus ADT alone: 78.2% vs 73.5% (HR 0.80). Conventional-imaging MFS was not statistically significant. #ESMO26 post hoc PSA-response analysis adds prognostic information. PROTEUS randomized substudy: new at #ESMO26: Perioperative apa/ADT + RP/PLND (n=102) v. immediate RP/PLND (n=306). At 37.8 months’ follow-up: • 3-year EFS: 63.0% vs 41.4%; HR 0.38. • Secondary PSMA-inclusive MFS: HR 0.49; nominal P=.0193. • Subsequent postoperative RT: 20% vs 43%. The substudy strengthens a "perioperative strategy". But conventional-imaging entry followed by PSMA-inclusive endpoints matters. PSA-based EFS, conventional MFS and PSMA-inclusive MFS are different endpoints. These trials support specific intensification strategies; they cannot rank the drugs or establish RP-versus-RT superiority. The decision remains who benefits enough to justify the ENTIRE treatment burden.
1
34
1
88
5,342
Melissa Abel, MD retweeted
Fair points, nicely laid out. With ADT, my top Q is: Does giving ADT now buy this patient sufficiently lower risk of something worse down the road? If 6m ADT with MDT only delays need for ADT in the future, that’s not good enough. Needs to ⬇️death or ⬆️treatment-free survival.
2
7
255
Melissa Abel, MD retweeted
Replying to @urotoday @tranpt21
Common pitfall: equating PSMA+ BCR with metastatic disease. @Dr_RaviMadan @melissaabel20
3
5
290
Melissa Abel, MD retweeted
Fresh off the oven!! Plasma cfchip predicts sclc subtypes. Hope to see a future where biopsies are not needed to classify sclc and using blood is as feasible. Much more to come on this frontier in near future!! jci.org/articles/view/202151…
2
2
3
795
Uncertain federal funding can delay all innovation. It means fewer promising treatments move forward; it means more lives lost to cancer.   We can underplay these things... as an abstract concept; it’s just a number on a page. But for people with cancer, this is their life. @ASCO
Thank you ASCO member Dr. @fumikochino for speaking on the importance of federal cancer research funding! #ASCOAdvocacy continues to urge Congress to pass a full, bipartisan FY27 bill to provide the strongest possible investments in medical research. youtube.com/watch?v=KYJnCFju…
1
3
25
1,688
Melissa Abel, MD retweeted
A beautiful explanation for why a drug should work tells you almost nothing about whether it will. That is where the wellness industry makes its money. Look at the chart below. In sixty years, even with the sharpest minds and richest labs on the planet, the share of drugs that fail in human testing hasn't changed. The clinical failure rate today, about 91%, sits exactly where it did in 1963, and not for lack of money. We spend about two and a half billion dollars for every one that survives. They fail because the mechanism was a confident guess. -> Raising good cholesterol was supposed to protect the heart, textbook biology, until Pfizer's pill did exactly that and killed more people than a placebo. -> Clearing plaque was supposed to cure Alzheimer's. Four hundred trials ran on that logic. Almost every one failed. So when a peptide seller walks you through a flawless diagram of why their product works, you're looking at the same kind of story that fooled the best-funded scientists. Biology isn't physics. You can't derive the answer on a whiteboard, and the cell doesn't care how clean your diagram looks. The only honest answer comes from the trial, and anyone who says they already know is selling you something.
Clinical attrition remains one of biotech's most humbling realities. A recent review found clinical failure rates of ~90% in the 1960s, ~80% in the 1970s/80s, and back to ~90%+ in the 2000s/2010 Source: sciencedirect.com/science/ar…
4
21
4
102
18,263
Melissa Abel, MD retweeted
What endpoints should we use when designing clinical trials for HR prostate cancer? Happy to share our @EurUrolOncol editorial where I,@RomDiamand and P. Kristanto look at this question and propose solutions. authors.elsevier.com/a/1nUXJ… @VickersBiostats @f2harrell @JulesBordet
2
3
24
2,848
Melissa Abel, MD retweeted
Many reasons to be cautious about overtreating BCR… Here’s how @LaurenOLoughli3 presents this complex discussion to pts: urotoday.com/video-lectures/…
2
5
1,523
Could not agree more with this thoughtful discussion on management of BCR. Even more relevant in the PSMA era, where scan findings are prompting treatment even for low risk BCR patients.
8
2,555
Melissa Abel, MD retweeted
Dr. Melissa Abel @melissaabel20 @theNCI discusses her Prospective #PSMA Imaging Trial w/@TDorffOnc including the potential clinical implications for management of #PSMA+ #BCR in #ProstateCancer urotoday.com/video-lectures/…
2
2
1
6
1,150
Melissa Abel, MD retweeted
Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO
52
2,039
444
5,556
2,634,873
Melissa Abel, MD retweeted
#ADREAM: ADT/ARPI stopped after 18 months for mHSPC patients with PSA <0.2. After being off treatment for 18 mo, 67% recovered T and 41% were still off ADT/ARPI with T recovery with median 24 mo off treatment. Meaningful data we can bring home from #ASCO26 to share with patients in clinic. @Daniel_J_George @hannahdzmd @urotoday @OncoDailyGU @OncoAlert @AtishChoudhury @ALLIANCE_org @AarmstrongDuke @DukeGUCancer
The #ADREAM trial from #ASCO26 offers insight into time off therapy for patients with metastatic prostate cancer and great response to ADT/ARPI. Important data from @ALLIANCE_org. @hannahdzmd @DCockrellMD @DukeGUCancer @AarmstrongDuke @DukeCancer
6
9
1,037
Melissa Abel, MD retweeted
#ASCO26 Talk about real-time updates. NEJM paper now online and my predictions and inferences appear true. Majority of MFS events were by PET not conventional imaging. "Most distant metastases were identified by PSMA PET (53.0% of those in the apalutamide group and 60.7% in the placebo group)" VERY IMPORTANTLY: "No significant between-group difference was observed in metastasis-free survival assessed with conventional imaging alone (hazard ratio, 0.84; 95% CI, 0.67 to 1.07)" Not only does MFS cross 1, but the HR also crosses the surrogate threshold effect (0.81). @urotoday @PCF_select @US_FDA
#ASCO26 The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published. Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret! @urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban
3
32
1
76
13,176
Key context here for PROTEUS. PSMA PFS and CI PFS are separate endpoints. Prognosis of 3-5 years from onset of mets is based on CI- will be much longer in PSMA+ recurrence. Not too surprising to have few CI PFS events @ 5 yr in pts who would have been historically labeled as BCR
Trials in localized prostate cancer are incredibly difficult to pull off, especially given the rapidly changing imaging and therapeutic landscape, so major congrats to the investigators. For me, top line results: small MFS benefit when MFS is defined by either conventional imaging or PSMA PET. No MFS benefit by conventional imaging. Critically, there were significant differences in PSMA PET utilization. Post hoc analysis showed that 686 patients (64.9%) in the apalutamide group and 755 patients (71.8%) in the placebo group underwent PSMA PET at least once. That difference is greater than the absolute MFS benefit (when MFS is defined by either conventional or PSMA imaging) and may mean that the MFS benefit is confounded by the differential use of PSMA PET at biochemical recurrence. The extent of that confounding will depend on the comparative probability of detecting Mets at BCR using PET vs conventional imaging in the trial cohort. Would be interested in that data. Does PROTEUS change practice? Given the above, I'm not sure the argument is there to go from RP alone (the current standard) to RP+ADT+ARPI. Will be interested in the substudy results. #ASCO26 #radonc #medtwitter #pcsm nejm.org/doi/full/10.1056/NE…
8
677
Melissa Abel, MD retweeted
Replying to @melissaabel20
@melissaabel20 @Dr_RaviMadan …super important and per your studies we really need to be measured around BCR patients and their PET results- far too often providers get nervous and pull the treatment trigger, inducing financial and tox cost w/o proven OS🤷🏻‍♂️
An important study that highlights the complexity of using PSMA PET as an endpoint. Prognostic significance of PSMA tumor volume varied between patients with low and high volume of disease (*particularly relevant for #PSMA+BCR):
2
4
399
An important study that highlights the complexity of using PSMA PET as an endpoint. Prognostic significance of PSMA tumor volume varied between patients with low and high volume of disease (*particularly relevant for #PSMA+BCR):
Clink link to article in European Urology. PSMA total tumour volume at 3months predicts overall survival independent of treatment in ENZAp. This raises important questions about how we should be measuring progression on PSMA. @ANZUPtrials @PCF_Science authors.elsevier.com/a/1mv80…
1
5
1
13
3,379
Melissa Abel, MD retweeted
Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/s…
4
21
3
91
11,136